Literature DB >> 14565842

Aripiprazole in an adult with Asperger disorder.

Jud A Staller1.   

Abstract

OBJECTIVE: To report a case of aripiprazole-responsive adult Asperger disorder. CASE
SUMMARY: A 34-year-old white man with lifelong, disabling Asperger disorder and a 20-year history of failed psychotherapeutic and pharmacologic interventions was prescribed aripiprazole, with dramatic symptomatic improvement. DISCUSSION: Multiple prior pharmacologic efforts over several years aimed predominantly at altering serotonin and dopamine neurotransmission resulted in treatment failure due to intolerable adverse effects, exacerbation of underlying symptoms, or nonresponse. Aripiprazole, with a complex profile of neurotransmitter affinities, has produced significant core symptom changes. Improved sociability; increased self-awareness; reduced rigidity, anxiety, and irritability; and reduced preoccupation with circumscribed esoteric interests are among the effects noted.
CONCLUSIONS: Previously intractable Asperger disorder symptoms in a 34-year-old man were ameliorated with aripiprazole.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14565842     DOI: 10.1345/aph.1D147

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

1.  Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder.

Authors:  Iain Jordan; Dene Robertson; Marco Catani; Michael Craig; Declan Murphy
Journal:  Psychopharmacology (Berl)       Date:  2012-04-26       Impact factor: 4.530

Review 2.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Aripiprazole treatment of Asperger's syndrome in the acute psychiatric setting: case report.

Authors:  Luiz Dratcu; Gavin McKay; Vinod Singaravelu; Venkat Krishnamurthy
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

4.  Aripiprazole in the acute treatment of male patients with schizophrenia: effectiveness, acceptability, and risks in the inner-city hospital setting.

Authors:  Luiz Dratcu; Patricia Olowu; Muzafar Hawramy; Charitomeni Konstantinidou
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

Review 5.  Aripiprazole for treating irritability in children & adolescents with autism: A systematic review.

Authors:  Ahmad Ghanizadeh; Sylvie Tordjman; Nematollah Jaafari
Journal:  Indian J Med Res       Date:  2015-09       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.